Evidence map›Paper›PMID 40353710›Full record

ArticleEuropean journal of breast health2025

Breast Angiosarcoma: Four Case Series and Literature Review.

Imen Bannour, Salma Ferjani, Hafedh Abbassi, Ekram Guerbej, Dorra Chiba, Sassi Boughizane, Badra Bannour

Abstract read
In one paragraph

Article in European journal of breast health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Imen BannourDepartment of Obstetrics and Gynecology, University of Sousse, Faculty of Medicine of Sousse, Farhat Hached Teaching Hospital, Sousse, Tunisia.ORCID 0009-0009-4497-6172
Salma FerjaniDepartment of Obstetrics and Gynecology, University of Sousse, Faculty of Medicine of Sousse, Farhat Hached Teaching Hospital, Sousse, Tunisia.ORCID 0009-0000-0556-6802
Hafedh AbbassiDepartment of Obstetrics and Gynecology, University of Sousse, Faculty of Medicine of Sousse, Farhat Hached Teaching Hospital, Sousse, Tunisia.ORCID 0000-0002-3547-1297
Ekram GuerbejDepartment of Obstetrics and Gynecology, University of Sousse, Faculty of Medicine of Sousse, Farhat Hached Teaching Hospital, Sousse, Tunisia.ORCID 0009-0007-2192-2476
Dorra ChibaDepartment of Pathology, University of Sousse, Faculty of Medicine of Sousse, Farhat Hached Teaching Hospital, Sousse, Tunisia.ORCID 0009-0006-7624-0299
Sassi BoughizaneDepartment of Obstetrics and Gynecology, University of Sousse, Faculty of Medicine of Sousse, Farhat Hached Teaching Hospital, Sousse, Tunisia.ORCID 0000-0001-8238-982X
Badra BannourDepartment of Obstetrics and Gynecology, University of Sousse, Faculty of Medicine of Sousse, Farhat Hached Teaching Hospital, Sousse, Tunisia.ORCID 0000-0003-3126-2233

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mammary angiosarcoma is a rare malignant mesenchymal tumor that develops from the vascular tissue of the breast. It represents 0.004 to 1% of all malignant breast tumors and 8 to 10% of breast sarcomas. It can be primary in a 40-year-old woman or radiation-induced in an older woman who has undergone conservative treatment for breast cancer, including conservative surgery and adjuvant radiotherapy. Herein, we present four cases involving breast angiosarcoma in young and relatively older women and the different treatment they received. Our discussion encompasses the epidemiological, diagnostic, and therapeutic facets of this rare and aggressive tumor type.

Indexed as

BRCA1 and BRCA2 genesbreast cancerbreast imagingmammographyprimary angiosarcoma

Identifiers

PMID40353710
PMCPMC12740286

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.